Alan Kaufman, MD
Allergy · Mount Vernon, NYNPI 1437150513
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.7%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by AstraZeneca at 56.3% of the total. Reporting peaked in 2019 at $25,847 and has fallen 90.5% since, to $2,449 in 2025. Among allergy clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 466 payments — averaging $128.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$34K
- Optinose US, Inc.$6K
- Genentech USA, Inc.$3K
- GSK$3K
- AbbVie$2K
- Regeneron$2K
- plus $11K from 25 others
Across 89 payments — averaging $1883.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$116K
- Astrazeneca UK Limited$26K
- Regeneron$25K
- Novartis$70
What the payments were for
- Consulting fees$4,5018%
- Speaking & faculty fees$32,72555%
- Travel & lodging$8001%
- Food & beverage$21,76436%
- Education$500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 103 | $33,711 |
| Optinose US, Inc. | 17 | $5,528 |
| Genentech USA, Inc. | 77 | $3,100 |
| GSK | 56 | $2,815 |
| AbbVie(2 entities) | 5 | $2,075 |
| Regeneron | 18 | $1,830 |
| Biocryst US Sales Co., LLC | 38 | $1,646 |
| Alk-abello, Inc | 18 | $1,343 |
| Sanofi | 31 | $1,328 |
| Pfizer | 20 | $977 |
| Regeneron Healthcare Solutions, Inc. | 18 | $677 |
| Halozyme Inc | 1 | $525 |
| Novartis | 16 | $512 |
| Beigene USA, Inc. | 1 | $475 |
| ADMA Biomanufacturing LLC | 2 | $386 |
| Genentech, Inc. | 6 | $349 |
| Incyte Corporation | 4 | $340 |
| CSL Behring | 8 | $337 |
| Dermavant Sciences, Inc. | 3 | $292 |
| Boehringer Ingelheim | 7 | $279 |
| Blueprint Medicines Corporation | 3 | $261 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $249 |
| Teva Pharmaceuticals USA, Inc. | 2 | $138 |
| Shire North American Group Inc | 1 | $122 |
| Mylan Specialty L.p. | 1 | $112 |
| Sunovion Pharmaceuticals Inc. | 1 | $111 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $99 |
| Greer Laboratories, Inc. | 1 | $96 |
| Kaleo, Inc. | 1 | $74 |
| Circassia Inc. | 3 | $43 |
| LEO Pharma Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$59,840 in reported general payments places this provider in the 90th percentile of 92 allergy providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 40 | $161,385 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 155 | $140,112 |
| XolairOmalizumab | 35 | $139,345 |
| FasenraBenralizumab | 12 | $67,780 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $7,876 |
| Azelastine Hcl | 164 | $5,836 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 107 | $4,713 |
| Fluticasone Propionate | 146 | $2,288 |
| Levocetirizine Dihydrochloride | 79 | $1,552 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 14 | $991 |
| Montelukast Sodium | 104 | $932 |
| Mometasone Furoate | 11 | $287 |
| Prednisone | 14 | $20 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $2,815 | $147,988167 claims |
| Genentech, Inc.Xolair | $349 | $139,34535 claims |
| AstraZenecaFasenra | $33,711 | $67,78012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 92 allergy providers in New York.
Other allergy in Mount Vernon
- Marc BraunsteinHewlett$884K
- Allison RamseyRochester$643K
- Christopher SmithHorseheads$622K
- Anne MaitlandTarrytown$292K
- Yudhistira PersaudBronx$127K
- Michael KatlanAlbany$91K
- Michel AklJamestown$90K
- Juan SotomayorNorth Syracuse$64K
- Alissa McInerneyAstoria$38K
- Audrey WeissmanElmhurst$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.